Netarsudil

Generic Name: Netarsudil

Brand Names: Rhopressa, Rocklatan, Rhokiinsa

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₇N_₃O_₃

CAS Number: 1254032-66-0

Unique Ingredient Identifier: W6I5QDT7QI

Background: A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous

As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.

Indication: Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension .

Associated Conditions: Increased Intra Ocular Pressure (IOP)

Clinical Trials

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Conditions: Fuchs Endothelial Corneal Dystrophy
Cataract
Glaucoma

Interventions: Drug: Netarsudil 0.02% Ophthalmic Solution
Drug: artificial tear substitute

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: University Hospital Dubrava

Target Recruit Count: 50

Registration Number: NCT06969586

Locations: 🇭🇷
University Hospital Dubrava, Zagreb, Croatia

The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)

Conditions: Pseudophakic Bullous Keratopathy
Glaucoma

Interventions: Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Drug: Placebo

First Posted Date: 2025-05-07

Last Posted Date: 2025-05-20

Lead Sponsor: University Hospital Dubrava

Target Recruit Count: 50

Registration Number: NCT06960629

Locations: 🇭🇷
University Hospital Dubrava, Zagreb, Croatia

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Phase 4

Not yet recruiting

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension

Interventions: Drug: Netarsudil ophthalmic solution 0.02%
Drug: Artificial tears

First Posted Date: 2025-03-07

Last Posted Date: 2025-05-14

Lead Sponsor: East Coast Institute for Research

Target Recruit Count: 70

Registration Number: NCT06865144

Locations: 🇺🇸
East Coast Institute for Research at Florida Eye Specialists, Jacksonville, Florida, United States

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Phase 4

Recruiting

Conditions: Normal Tension Glaucoma

Interventions: Drug: Brimonidine
Drug: Netarsudil

First Posted Date: 2024-06-10

Last Posted Date: 2024-06-26

Lead Sponsor: Westlake Eye Specialists

Target Recruit Count: 100

Registration Number: NCT06449352

Locations: 🇺🇸
Westlake Eye Specialists - New Braunfels Office, New Braunfels, Texas, United States
🇺🇸
Westlake Eye Specialists - Kyle Office, Kyle, Texas, United States
🇺🇸
Westlake Eye Specialists - Austin Office, Austin, Texas, United States

and more 1 locations

Next Generation Rocklatan

Phase 2

Not yet recruiting

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: AR-17043 Ophthalmic Solution
Drug: AR-17043 Vehicle
Drug: Netarsudil 0.02% Ophthalmic Solution
Drug: PG043 Ophthalmic Solution
Drug: Latanoprost 0.005% Ophthalmic Solution
Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

First Posted Date: 2024-06-04

Last Posted Date: 2024-06-04

Lead Sponsor: Alcon Research

Target Recruit Count: 450

Registration Number: NCT06441643

Locations: 🇺🇸
Orange County Ophthalmology Medical Group, Garden Grove, California, United States
🇺🇸
United Medical Research Institute, Inglewood, California, United States
🇺🇸
Eye Research Foundation, Newport Beach, California, United States

and more 9 locations

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Phase 2

Active, not recruiting

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: T4090 0.2%
Drug: T4090 0.3%
Drug: Rhopressa®

First Posted Date: 2024-05-01

Last Posted Date: 2024-10-04

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 126

Registration Number: NCT06394973

Locations: 🇺🇸
Arizona Advanced Eye Research Institute, Glendale, Arizona, United States
🇺🇸
Global Research Management, Inc., Glendale, California, United States
🇺🇸
United Medical Research Institute, Inglewood, California, United States

and more 20 locations

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients with Retinal Detachment

Phase 1

Not yet recruiting

Conditions: Proliferative Vitreoretinopathy
Rhegmatogenous Retinal Detachment

Interventions: Drug: Netarsudil Ophthalmic

First Posted Date: 2023-09-13

Last Posted Date: 2024-11-25

Lead Sponsor: Massachusetts Eye and Ear Infirmary

Target Recruit Count: 48

Registration Number: NCT06033703

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Phase 2

Active, not recruiting

Conditions: Proliferative Vitreoretinopathy
Rhegmatogenous Retinal Detachment

Interventions: Drug: Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]

First Posted Date: 2022-12-21

Last Posted Date: 2024-07-30

Lead Sponsor: Wills Eye

Target Recruit Count: 80

Registration Number: NCT05660447

Locations: 🇺🇸
Wills Eye Physicians - Mid Atlantic Retina, Philadelphia, Pennsylvania, United States

Rocklatan® Evaluation

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution

First Posted Date: 2022-03-17

Last Posted Date: 2024-04-03

Lead Sponsor: Aerie Pharmaceuticals

Target Recruit Count: 136

Registration Number: NCT05283395

Locations: 🇺🇸
Keystone Research, Austin, Texas, United States
🇺🇸
Total Eye Care, PA, Memphis, Tennessee, United States
🇺🇸
North Valley Eye Medical Group, Mission Hills, California, United States

and more 18 locations

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Phase 4

Conditions: Normal Tension Glaucoma

Interventions: Drug: Netarsudil Ophthalmic
Drug: Bimatoprost Ophthalmic

First Posted Date: 2021-07-29

Last Posted Date: 2021-08-06

Lead Sponsor: Salus University

Target Recruit Count: 115

Registration Number: NCT04981886

Locations: 🇺🇸
Roberts Eyecare Associates, Vestal, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy